DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で28.70%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 4.66Bです。
割安
同社の最新のPEは31.16で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は384.48M株で、前四半期比で5.90%減少しています。
ジェームズ・シモンズが保有
スター投資家ジェームズ・シモンズは本銘柄を0.00株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.07です。